PCOS is now called PMOS: a new name full of hope
What this means and why I’m cautiously hopeful
Hello everyone,
You probably have heard rumours that PCOS is getting a new name. Well, it’s finally here:
PMOS = polyendocrine metabolic ovarian syndrome
If before you were a woman diagnosed with PCOS, from today onwards, you are acquiring a new name, PMOS. If you have made this condition your identity (guilty ME), this rebrand might feel odd, like you are changing your last name when you marry. Jokes aside, this new name has the potential to really advance this condition.
It is not a treatment. It is something that might, if handled well, change the way PCOS is understood, funded, and managed for the next generation of women going through diagnosis.
Let’s dive into it.
A Health Policy paper published today, 12 May 2026, in The Lancet has confirmed that polycystic ovary syndrome has a new name: polyendocrine metabolic ovarian syndrome, or PMOS. This was agreed through an unprecedented, multi-year global consensus process, and is now published with a full implementation strategy. Some serious work has gone into this name change behind the scenes.
What does the new name actually mean
Polyendocrine — the “poly” prefix acknowledges that this is not a single hormonal disruption. PMOS involves multiple interacting endocrine mechanisms: elevated testosterone (from both the ovaries and often the adrenal glands), FSH/LH signalling to the ovaries, and insulin resistance.
Metabolic — insulin resistance affects approximately 85% of people with PMOS, including 75% of lean women with a BMI of 25 or below. Calling it "metabolic" acknowledges that there are issues with how we process energy and how that affects our health.
Ovarian — ovarian dysfunction continues to be a defining feature, including irregular periods, arrested follicles (the cysts) and failed ovulation.
As you notice, the cysts are dropped from the name for a good reason. The “cysts” in the old name were always arrested follicles, not cysts in any clinical sense, and it often made it look like a purely reproductive issue.
My thoughts and concerns
I think this is genuinely significant. The process was rigorous, the scale of engagement was big and thought through, and the name makes a lot of sense. A lot of work went into it, and I really hope it generates the impact it deserves.
For those of us who have spent years being bounced between departments, had our metabolic or psychological features ignored, or been told PCOS was a fertility problem and nothing else, I hope this name brings better care.
But I have two things I want to say honestly.
Will metabolic = just lose weight?
This is the one I feel more strongly about, and I want to be direct. If PMOS is widely understood as a “metabolic condition,” there is a real risk that clinical and public perception defaults to weight as both the cause and the solution.
I worry about people being made to feel that it is their fault because they ate too much or didn’t move enough, so they ended up with a “metabolic” disease.
“Metabolic” does not mean “caused by excess weight.” It means relating to the complex biochemical systems that govern energy, hormones, inflammation, androgen signalling, and insulin sensitivity, systems that are dysregulated in PMOS across a wide range of body types, and not simply resolved by weight loss.
The condition that has historically been dismissed as “just a gynaecological thing” should not become a condition dismissed as “just a weight thing.” That would be a different kind of failure, and one we will need to push back on clearly if the narrative goes that way.
Will we get more research?
A name change is a necessary but not sufficient step. What people with PMOS need urgently is investment in understanding the different phenotypes: why two people with the same diagnosis can have almost nothing in common clinically, and what that means for what will work for each person. We still do not have a clear, phenotype-specific evidence base for management. The name change needs to be a door that opens into accelerated, better-funded, phenotype-aware research. I will be watching carefully to see whether research funding actually diversifies, or whether “metabolic” simply becomes a new label on the same reproductive-focused evidence base.
Why PMOS? How the name was chosen
The preferred terms that emerged consistently from the surveys were polyendocrine, metabolic, and ovarian. “Metabolic endocrine reproductive syndrome” was excluded because its acronym duplicated that of Middle East respiratory syndrome. “Endocrine metabolic ovulatory syndrome” (EMOS) initially ranked at the top but was found to overlap with a youth subculture, and “ovulatory” was considered too narrow, irrelevant beyond the reproductive years, and insufficient to capture the full ovarian picture.
Survey B in January 2026 asked participants to rate finalised combinations. Polyendocrine metabolic ovarian syndrome received 66% support from patients and 57% from health professionals as the top-ranked name.
The new acronym PMOS retains visual similarity to PCOS, a deliberate choice. The implementation approach was framed as evolutionary rebranding, updating, not replacing, to make the transition more feasible in practice.
Who is behind it
Previous attempts to rename PCOS have failed. Calls to change the name date back to 1995. The NIH recommended renaming in 2012. Experts, patient groups, and researchers have been making the case for decades, and every attempt has stalled, largely because there was no coordinated global process, no agreed-upon alternative name, and no implementation strategy.
The process was led by Monash University’s Centre for Research Excellence in Women’s Health in Reproductive Life, the Androgen Excess and PCOS Society, and Verity, the UK patient charity that reinvigorated the renaming initiative in 2023. It was funded by the Australian National Health and Medical Research Council, which matters because it meant there were real resources behind the process, not just goodwill.
The methodology used was a multistep combination of global Delphi surveys, Nominal Group Technique workshops, and a professional marketing and communication analysis. This is a rigorous, structured consensus approach, the same kind of framework used in major international health policy decisions. It was designed to be transparent, globally representative, and grounded in both scientific evidence and lived experience.
The process ran from 2024 to February 2026.
How big was the effort?
Building on 7,708 survey responses from prior phases in 2015 and 2023, this new process generated a further 14,360 responses — from 10,411 people with PCOS and 3,949 health professionals from all world regions. 56 leading academic, clinical, and patient organisations were engaged.
Two global surveys were run. Two international consensus workshops were held,one in November 2025 and one in February 2026, with approximately 90 representatives from multiple world regions in each, co-chaired by people with PCOS and health professionals alike, with independent observers overseeing the process.
The surveys were available in English, Chinese, German, Persian, and Malaysian. Every stage, governance, survey design, workshop recruitment, interpretation of results, and the implementation strategy included people with PCOS as active contributors with shared power, not as a token consultation.
On the core question of approach, 86% of people with PCOS and 71% of health professionals voted for an accurate, symptom-based new name rather than retaining the PCOS acronym with different words, or adopting a generic umbrella name.
What might practically change
Referral pathways. A name that signals endocrinology and metabolic medicine creates a legitimate basis for earlier referrals to endocrinologists and for multidisciplinary care to be expected rather than exceptional. The default route through gynaecology has never served women whose metabolic, psychological, or cardiovascular manifestations were the most significant part of their experience.
Research funding. The paper notes PCOS research has been “largely restricted to reproductive schemes,” which has constrained the entire evidence base. A condition classified as polyendocrine-metabolic can legitimately compete for endocrinology, cardiovascular, and metabolic disease funding - hopefully a much bigger pocket.
Medical education. PCOS is currently absent from pregnancy textbooks and midwifery and obstetrics education programmes. If PMOS is coded within endocrinology and metabolic medicine in the ICD, which the implementation strategy specifically plans to pursue, there is a meaningful basis for it appearing across specialities, not just in gynaecology.
Diagnosis. Up to 70% of affected individuals are thought to remain undiagnosed. Confusion around the current name has contributed to this — both because patients don’t connect their symptoms to an “ovary” problem, and because clinicians outside gynaecology may not think of PCOS as within their remit.
The implementation strategy is an eight-stage plan covering: academic dissemination; multilingual resource development; global communication; integration into electronic health records and SNOMED coding; engagement with research funders and journal editors; formal engagement with WHO and the ICD; a managed three-year transition period; and integration into the 2028 update of the International Guidelines, currently used in 195 countries.
During the transition, the condition will be referred to as “the condition formerly known as PCOS.” Your GP, research databases, and patient resources will likely still say PCOS for some time, and that’s expected and planned for.
Conclusion
This is one of the more significant developments in this space in a long time. The condition affects one in ten women globally. It has been misnamed, miscategorised, underfunded, and underdiagnosed for decades. An imperfect name isn’t the only reason for that, but it has been a structural one.
I will continue to cover this here as the implementation unfolds with the ICD coding changes, the International Guidelines update in 2028, and as the research landscape hopefully begins to shift.
As always, I would love to hear your thoughts. Does the new name feel right to you? Does it change anything about how you understand your own diagnosis?
See you next Sunday,
Francesca
Teede, H.J., Bahri Khomami, M., Morman, R. et al. (2026) ‘Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process’, The Lancet, published online 12 May 2026. DOI: https://doi.org/10.1016/S0140-6736(26)00717-8